TV News LIES

Sunday, Mar 01st

Last update07:31:12 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Tobacco giants resist harsh public admissions about smoking

Tobacco companies deny dangersNever underestimate the staying power of big tobacco.In 2006, U.S. District Judge Gladys Kessler ordered the...

New drug shields monkeys from AIDS: study

HIV vaccine a success in monkeysScientists said Wednesday a new drug tested on monkeys provided an astonishingly effective shield against an...

2 dead, 179 exposed after 'superbug' outbreak at L.A. hospital

LA hospital superbugContaminated medical instruments are to blame for infecting seven patients, including two who died, with a...

Fatal birth defect stalks 3 Central Wash. counties

Fatal birth defects washington stateNearly three years after nurse Sara Barron first sounded the alarm about a spike in rare...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!